Anti-Cancer Drug Market is expected to grow from USD 150.6 billion in 2022 to USD 266.5 billion by 2030 : GreyViews Pune India, Jan. 03, 2023 (GLOBE NEWSWIRE) -- The market has been studied for the below mentioned-segmentation and regional analysis for North America, Europe, Asia, South America, and the Middle...

Kalos Therapeutics, Inc., Oncology Pharmaceuticals and NanoSmart Pharmaceuticals, Inc., Combination Therapy Offers the Potential of a Safer and More Effective Approach to a Wide Variety of Cancer Treatments SAN FRANCISCO, CA, Sept. 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Oncology Pharma (OTCPK: ONPH) is pleased to announce that Kalos Therapeutics' lead compound, KTH-222, can produce a reduction...

Oncology Pharma Signed a Letter of Intent with Kalos Therapeutics for an Exclusive World-Wide Licence and Co-Devlopent of Its Broad-Spectrum Anti-Cancer Drug, KTH 222 SAN FRANCISCO, CA, Aug. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Oncology Pharma (OTCPK: ONPH) is pleased to announce that it signed a Letter of Intent with Kalos Therapeutics (Phoenix, AZ)...